Management of patients with Arrhythmogenic Right Ventricular Cardiomyopathy in the Nordic countries

Scandinavian Cardiovascular Journal

Volumn 49, Issue 6, 2015, Pages 299-307

  Haugaa, Kristina H ^a,i   Bundgaard, Henning ^b   Edvardsen, Thor ^a,i   Eschen, Ole ^c   Gilljam, Thomas ^d   Hansen, Jim ^e   Jensen, Henrik Kjærulf ^f   Platonov, Pyotr G ^g   Svensson, Anneli ^h   Svendsen, Jesper H ^e,j  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g LUND UNIVERSITY   (Sweden)

^h LINKÖPING UNIVERSITY   (Sweden)

ⁱ UNIVERSITY OF OSLO   (Norway)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

arrhythmogenic right ventricular cardiomyopathy; Management of ARVC; mutation positive family members; Ventricular arrhythmias

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IVABRADINE; LOOP DIURETIC AGENT; SOTALOL; SPIRONOLACTONE; CARDIOVASCULAR AGENT;

ANGIOCARDIOGRAPHY; ARRHYTHMOGENESIS; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGIST; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CATHETER ABLATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DENMARK; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FINLAND; FOLLOW UP; GENE MUTATION; HEART FAILURE; HEART MUSCLE BIOPSY; HEART RIGHT VENTRICLE DYSPLASIA; HEART TRANSPLANTATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; NORWAY; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SPORT; SWEDEN; ADVERSE EFFECTS; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CARDIOVERSION; DEATH, SUDDEN, CARDIAC; DEVICES; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; MORTALITY; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; SCANDINAVIA; TREATMENT OUTCOME;

ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CARDIOVASCULAR AGENTS; CATHETER ABLATION; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SCANDINAVIAN AND NORDIC COUNTRIES; TREATMENT OUTCOME;

EID: 84942236515     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2015.1086017     Document Type: Article

References (35)

1. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010; 121: 1533-41.
2. Saberniak J, Hasselberg NE, Borgquist R, Platonov PG, Sarvari SI, Smith HJ, et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail. 2014; 16: 1337-44.
3. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013; 62: 1290-7.
4. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2006; 48: e247-e346.
5. Corrado D, Basso C, Pilichou K, Thiene G. Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart. 2011; 97: 530-9.
6. Peters S, Peters H, Thierfelder L. Risk stratification of sudden cardiac death and malignant ventricular arrhythmias in right ventricular dysplasia-cardiomyopathy. IntJCardiol. 1999; 71: 243-50.
7. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011; 58: 1485-96.
8. Corrado D, Leoni L, Link MS, Della BP, Gaita F, Curnis A, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003; 108: 3084-91.
9. Turrini P, Corrado D, Basso C, Nava A, Bauce B, Thiene G. Dispersion of ventricular depolarization-repolarization: a noninvasive marker for risk stratification in arrhythmogenic right ventricular cardiomyopathy. Circulation. 2001; 103: 3075-80.
10. Sarvari SI, Haugaa KH, Anfinsen OG, Leren TP, Smiseth OA, Kongsgaard E, et al. Right ventricular mechanical dispersion is related to malignant arrhythmias: a study of patients with arrhythmogenic right ventricular cardiomyopathy and subclinical right ventricular dysfunction. EurHeart J. 2011; 32: 1089-96.
11. Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JD, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathyassociated mutation carriers. Eur Heart J. 2015; 36: 847-55.
12. Link MS, Laidlaw D, Polonsky B, Zareba W, McNitt S, Gear K, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. J Am Coll Cardiol. 2014; 64: 119-25.
13. Wichter T, Schulze-Bahr E, Eckardt L, Paul M, Levkau B, Meyborg M, et al. Molecular mechanisms of inherited ventricular arrhythmias. Herz. 2002; 27: 712-39.
14. Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J. 2015.
15. Marcus FI, Fontaine G. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: a review. Pacing Clin Electrophysiol. 1995; 18: 1298-314.
16. Gemayel C, Pelliccia A, Thompson PD. Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2001; 38: 1773-81.
17. Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol. 2009; 54: 609-15.
18. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. EurHeart J. 2012; 33: 1787-847.
19. Maury P, Baratto F, Zeppenfeld K, Klein G, Delacretaz E, Sacher F, et al. Radio-frequency ablation as primary management of well-tolerated sustained monomorphic ventricular tachycardia in patients with structural heart disease and left ventricular ejection fraction over 30%. Eur Heart J. 2014; 35: 1479-85.
20. Wijnmaalen AP, Schalij MJ, Bootsma M, Kies P, AD ER, Putter H, et al. Patients with scar-related right ventricular tachycardia: determinants of long-term outcome. Journal of cardiovascular electrophysiology. 2009; 20: 1119-27.
21. Bai R, Di Biase L, Shivkumar K, Mohanty P, Tung R, Santangeli P, et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circulation Arrhythmia and electrophysiology. 2011; 4: 478-85.
22. Philips B, Madhavan S, James C, Tichnell C, Murray B, Dalal D, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. CircArrhythmElectrophysiol. 2012; 5: 499-505.
23. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2011; 13: 1077-109.
24. Borgquist R, Haugaa KH, Gilljam T, Bundgaard H, Hansen J, Eschen O, et al. The diagnostic performance of imaging methods in ARVC using the 2010 Task Force criteria. European heart journal cardiovascular Imaging. 2014; 15: 1219-25.
25. Inciardi RM, Rotolo A, Coppola G, Clemenza F, Giordano U, Lombardo E, et al. Treatment decision making in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: state of the art. IntJCardiol. 2014; 174: 191-2.
26. Bauce B, Daliento L, Frigo G, Russo G, Nava A. Pregnancy in women with arrhythmogenic right ventricular cardiomyopathy/dysplasia. EurJObstetGynecolReprodBiol. 2006; 127: 186-9.
27. Murray B, Tichnell C, James C, Tandri H, Calkins H. Pregnancy in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J AmCollCardiol. 2013; 62: 1910-1.
28. Agir A, Bozyel S, Celikyurt U, Argan O, Yilmaz I, Karauzum K, et al. Arrhythmogenic right ventricular cardiomyopathy in pregnancy. IntHeart J. 2014; 55: 372-6.
29. Krul SP, van der Smagt JJ, van den Berg MP, Sollie KM, Pieper PG, van Spaendonck-Zwarts KY. Systematic review of pregnancy in women with inherited cardiomyopathies. European journal of heart failure. 2011; 13: 584-94.
30. Ruwald AC, Marcus F, Estes NA, 3rd, Link M, McNitt S, Polonsky B, et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2015; 36: 1735-43.
31. Perrin MJ, Angaran P, Laksman Z, Zhang H, Porepa LF, Rutberg J, et al. Exercise testing in asymptomatic gene carriers exposes a latent electrical substrate of arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2013; 62: 1772-9.
32. Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009; 373: 1289-300.
33. Heidbuchel H, Corrado D, Biffi A, Hoffmann E, Panhuyzen-Goedkoop N, Hoogsteen J, et al. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators. EurJ Cardiovasc PrevRehabil. 2006; 13: 676-86.
34. Pelliccia A, Zipes DP, Maron BJ. Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol. 2008; 52: 1990-6.
35. Pelliccia A, Fagard R, Bjornstad HH, Anastassakis A, Arbustini E, Assanelli D, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. EurHeart J. 2005; 26: 1422-45.